OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
March 03, 2024
Activation and expansion are essential for success in both autologous and allogeneic therapies.
This article explores the emergence of subjectivity in ICH Q9 (R1).
March 02, 2024
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.
Swissmedic issues updated guidance relating to APIs, temporary authorization, and fast-track authorizations.
Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.
While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.
The license holder should negotiate, educate, contract, and then oversee the transportation contractor, says Siegfried Schmitt, vice president, Technical at Parexel.
Distek has released the BIOne 250 Bioprocess Controller, designed for microbial applications.